Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hjorth

Showing results (21-30 of 54) with videos related to

Pageof 6
Sort By:
Physical Review Letters|August 16, 2011
Quenching of spectroscopic factors for proton removal in oxygen isotopesØ Jensen, G Hagen, M Hjorth-Jensen, et al.
Environmental Technology|July 10, 2008
Interactions between phosphorus feeding strategies for pigs and dairy cows and separation efficiency of slurryS G Sommer, M Maahn, H D Poulsen, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Interferon therapy during the plateau phase of multiple myeloma: an update of the Swedish studyJ Westin, A Cortelezzi, M Hjorth, et al.
Physical Review Letters|April 20, 2004
Coupled cluster calculations of ground and excited states of nucleiK Kowalski, D J Dean, M Hjorth-Jensen, et al.
British Journal of Haematology|March 1, 1995
Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Cooperative Study GroupJ Westin, S Rödjer, I Turesson, et al.
Physical Review Letters|August 7, 2012
Evolution of shell structure in neutron-rich calcium isotopesG Hagen, M Hjorth-Jensen, G R Jansen, et al.
European Journal of Haematology|May 5, 1999
Survival in conventionally treated younger (<60 years) multiple myeloma patients: no improvement during two decades. Nordic Myeloma Study Group (NMSG)M Hjorth, E Holmberg, S Rödjer, et al.
European Journal of Haematology|February 1, 1993
Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western SwedenM Hjorth, L Hellquist, E Holmberg, et al.
European Journal of Haematology|June 26, 2001
Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myelomaN Gulbrandsen, F Wisløff, E Nord, et al.
Physical Review Letters|September 26, 2012
Continuum effects and three-nucleon forces in neutron-rich oxygen isotopesG Hagen, M Hjorth-Jensen, G R Jansen, et al.
Pageof 6

Showing results (21-30 of 54) with videos related to

Sort By:
Pageof 6
Physical Review Letters|August 16, 2011
Quenching of spectroscopic factors for proton removal in oxygen isotopesØ Jensen, G Hagen, M Hjorth-Jensen, et al.
Environmental Technology|July 10, 2008
Interactions between phosphorus feeding strategies for pigs and dairy cows and separation efficiency of slurryS G Sommer, M Maahn, H D Poulsen, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Interferon therapy during the plateau phase of multiple myeloma: an update of the Swedish studyJ Westin, A Cortelezzi, M Hjorth, et al.
Physical Review Letters|April 20, 2004
Coupled cluster calculations of ground and excited states of nucleiK Kowalski, D J Dean, M Hjorth-Jensen, et al.
British Journal of Haematology|March 1, 1995
Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Cooperative Study GroupJ Westin, S Rödjer, I Turesson, et al.
Physical Review Letters|August 7, 2012
Evolution of shell structure in neutron-rich calcium isotopesG Hagen, M Hjorth-Jensen, G R Jansen, et al.
European Journal of Haematology|May 5, 1999
Survival in conventionally treated younger (<60 years) multiple myeloma patients: no improvement during two decades. Nordic Myeloma Study Group (NMSG)M Hjorth, E Holmberg, S Rödjer, et al.
European Journal of Haematology|February 1, 1993
Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western SwedenM Hjorth, L Hellquist, E Holmberg, et al.
European Journal of Haematology|June 26, 2001
Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myelomaN Gulbrandsen, F Wisløff, E Nord, et al.
Physical Review Letters|September 26, 2012
Continuum effects and three-nucleon forces in neutron-rich oxygen isotopesG Hagen, M Hjorth-Jensen, G R Jansen, et al.
Pageof 6